Peptides

Tesamorelin

Evidence: Strong (FDA-approved indication), Moderate (longevity)

Mechanism of Action

Tesamorelin is an FDA-approved synthetic 44-amino acid GHRH analog with a trans-3-hexenoic acid modification at the N-terminal tyrosine that confers resistance to DPP-IV degradation. It binds GHRH receptors on anterior pituitary somatotrophs, stimulating endogenous GH production and secretion while maintaining pulsatile release patterns. Tesamorelin selectively reduces visceral adipose tissue (15-20% reduction in trials) while preserving subcutaneous fat, and markedly increases plasma GH and IGF-1 levels with once-daily dosing.

Dosing Protocol

Standard: Research indicates 2 mg administered once daily via subcutaneous injection (FDA-approved dose for HIV lipodystrophy).

Maintenance: Research indicates 1-2 mg daily. Effects reverse upon discontinuation.

Administration: subcutaneous

Timing: Morning administration on empty stomach. Consistent daily timing recommended.

Duration: 26+ weeks in clinical trials. Long-term use is common; effects are not sustained after discontinuation.

Notes

Tesamorelin is the gold standard for evidence-based GH optimization — it is FDA-approved (2010) with robust Phase III data. Pivotal trials showed 15-20% visceral fat reduction in 26 weeks. It is the only GHRH analog with regulatory approval. Effects reverse upon discontinuation, suggesting continuous use is needed. The pharmaceutical cost is high; compounding pharmacy versions are more accessible. Off-label use for body composition optimization in non-HIV populations is common in the optimization community.

Stacking

  • Ipamorelin
  • AOD-9604

Interactions

  • Insulin/Antidiabetics [HIGH] — GH elevation impairs insulin sensitivity; monitor glucose.
  • Glucocorticoids [MEDIUM] — May reduce tesamorelin efficacy.
  • Antiretrovirals [LOW] — Approved for use alongside HIV antiretroviral therapy.
  • May reduce efficacy of cortisol-based medications
  • Interacts with insulin (monitor blood glucose)

Contraindications

  • Active cancer or pituitary tumors
  • Pregnancy (Category X)
  • Hypersensitivity to GHRH analogs
  • Disruption of hypothalamic-pituitary axis from surgery/radiation
  • Active cancer
  • Pregnancy
  • Pituitary surgery or disease

Side Effects

  • Injection site reactions (erythema, pruritus)
  • Arthralgia
  • Peripheral edema
  • Myalgia
  • Paresthesia
  • Elevated blood glucose

Key Papers

  • 10.1056/NEJMoa1001108
  • 10.1371/journal.pone.0004819
  • Falutz et al. 2007 - Tesamorelin reduces visceral fat (NEJM)

Source Quality

Pharmaceutical-grade (marketed as EGRIFTA). Also available through compounding pharmacies. The only FDA-approved GHRH analog currently on market.

Disclaimer: This information is for educational purposes only and is not medical advice. BioAccelera Labs does not diagnose, treat, or prescribe. Consult a licensed healthcare provider before using any compound.

Should Tesamorelin Be in Your Stack?

Take the free assessment and get personalized recommendations based on your biology and goals.

Get Your Free Protocolor take the assessment →
← Browse All 231 Compounds